Search results for "61"

showing 10 items of 3634 documents

Exclusive transduction of human CD4+ T Cells upon systemic delivery of CD4-targeted lentiviral vectors

2015

Abstract Playing a central role in both innate and adaptive immunity, CD4+ T cells are a key target for genetic modifications in basic research and immunotherapy. In this article, we describe novel lentiviral vectors (CD4-LV) that have been rendered selective for human or simian CD4+ cells by surface engineering. When applied to PBMCs, CD4-LV transduced CD4+ but not CD4− cells. Notably, also unstimulated T cells were stably genetically modified. Upon systemic or intrasplenic administration into mice reconstituted with human PBMCs or hematopoietic stem cells, reporter gene expression was predominantly detected in lymphoid organs. Evaluation of GFP expression in organ-derived cells and blood …

CD4-Positive T-Lymphocytes10028 Institute of Medical VirologyCell TransplantationGenetic enhancementAdoptiveMice SCIDImmunotherapy AdoptiveInterleukin 21MiceMice Inbred NODTransduction GeneticBone MarrowLeukocytesImmunology and AllergyCytotoxic T cellIL-2 receptorLuciferasesCells CulturedMice KnockoutHeterologousTumorCulturedForkhead Transcription FactorsAcquired immune systemFlow Cytometry3. Good healthCell biologymedicine.anatomical_structure[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology2723 Immunology and Allergy[SDV.IMM]Life Sciences [q-bio]/ImmunologyImmunotherapyRegulatory T cellCellsKnockoutTransplantation HeterologousImmunologyMononuclearGenetic VectorsGreen Fluorescent Proteins610 Medicine & healthStreptamerThymus GlandBiologySCIDCell LineTransductionGeneticCell Line TumormedicineAnimalsHumansInterleukin 3Transplantation2403 ImmunologyLentivirusGenetic TherapyMolecular biology[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyHEK293 CellsLeukocytes MononuclearInbred NOD570 Life sciences; biologySpleen
researchProduct

Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted al…

2009

Donor lymphocyte infusions (DLI) are used to resolve mixed T-cell chimerism (TCC) after allo-SCT despite a substantial risk of GVHD. We analyzed the impact of prophylactic CD8-depleted (CD8(depl)) DLI in 20 recipients of anti-CD52 alemtuzumab in vivo T-cell-depleted allografts with declining donor TCC after day +60. A total of 13 patients received CD8(depl) DLI and 7 patients did not. All but one of the DLI patients converted to complete donor T-cell chimeras, whereas only one non-DLI patient converted spontaneously. DLI induced transient acute GVHD in five and extensive chronic GVHD in two patients. These data suggest the use of CD8(depl) DLI as an effective treatment for mixed TCC, partic…

CD4-Positive T-LymphocytesAntibodies NeoplasmLymphocytemedicine.medical_treatmentHematopoietic stem cell transplantation*Lymphocyte DepletionT-Lymphocyte SubsetsAlemtuzumabddc:616Transplantation Chimera/*immunologyHematopoietic Stem Cell TransplantationAntibodies MonoclonalHematologyMiddle Agedmedicine.anatomical_structureCD52 AntigenLymphocyte TransfusionAlemtuzumabmedicine.drug*GlycoproteinsAdultCD52T cellAntibodies Monoclonal/therapeutic useAntineoplastic AgentsCD4-Positive T-Lymphocytes/*transplantationAntibodies Monoclonal HumanizedLymphocyte DepletionAntigens CDAntigens NeoplasmmedicineAntibodies Neoplasm/therapeutic useHumans*Peripheral Blood Stem Cell TransplantationAgedCell ProliferationGlycoproteinsLymphocyte Transfusion/*methodsTransplantationPeripheral Blood Stem Cell TransplantationTransplantation Chimerabusiness.industryAntineoplastic Agents/therapeutic usemedicine.diseaseTransplantationGraft-versus-host disease*Antigens NeoplasmImmunology*Antigens CDbusinessCD8Bone marrow transplantation
researchProduct

SOCS3 transactivation by PPARγ prevents IL-17-driven cancer growth.

2013

Abstract Activation of the transcription factor PPARγ by the n-3 fatty acid docosahexaenoic acid (DHA) is implicated in controlling proinflammatory cytokine secretion, but the intracellular signaling pathways engaged by PPARγ are incompletely characterized. Here, we identify the adapter-encoding gene SOCS3 as a critical transcriptional target of PPARγ. SOCS3 promoter binding and gene transactivation by PPARγ was associated with a repression in differentiation of proinflammatory T-helper (TH)17 cells. Accordingly, TH17 cells induced in vitro displayed increased SOCS3 expression and diminished capacity to produce interleukin (IL)-17 following activation of PPARγ by DHA. Furthermore, naïve CD4…

CD4-Positive T-LymphocytesCancer ResearchAngiogenesisMammary Neoplasms Experimental/genetics/pathology/prevention & controlSuppressor of Cytokine Signaling Proteinsddc:616.07BioinformaticsTransactivationMice0302 clinical medicineTumor Burden/drug effects/geneticsSOCS3Docosahexaenoic Acids/administration & dosage/pharmacologyPromoter Regions GeneticMice Knockout0303 health sciencesMice Inbred BALB CChemistryReverse Transcriptase Polymerase Chain ReactionInterleukin-17InterleukinCell DifferentiationCell biologyTumor BurdenOncology030220 oncology & carcinogenesisFemaleRNA InterferenceInterleukin 17Th17 Cells/drug effects/metabolismTranscriptional ActivationDocosahexaenoic AcidsBlotting WesternMice NudeCD4-Positive T-Lymphocytes/drug effects/metabolismProinflammatory cytokine03 medical and health sciencesSuppressor of Cytokine Signaling Proteins/genetics/metabolismCell Line TumorAnimalsTranscription factor030304 developmental biologyMammary Neoplasms ExperimentalPromoter Regions Genetic/geneticsDietMice Inbred C57BLPPAR gammaInterleukin-17/metabolismCell cultureSuppressor of Cytokine Signaling 3 ProteinCell Differentiation/drug effectsPPAR gamma/agonists/genetics/metabolismTh17 CellsCancer research
researchProduct

Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of pati…

2000

NY-ESO-1 is a member of the cancer-testis family of tumor antigens that elicits strong humoral and cellular immune responses in patients with NY-ESO-1–expressing cancers. Since CD4+ T lymphocytes play a critical role in generating antigen-specific cytotoxic T lymphocyte and antibody responses, we searched for NY-ESO-1 epitopes presented by histocompatibility leukocyte antigen (HLA) class II molecules. Autologous monocyte-derived dendritic cells of cancer patients were incubated with recombinant NY-ESO-1 protein and used in enzyme-linked immunospot (ELISPOT) assays to detect NY-ESO-1–specific CD4+ T lymphocyte responses. To identify possible epitopes presented by distinct HLA class II allele…

CD4-Positive T-LymphocytesImmunologyMolecular Sequence DataAntigen-Presenting Cells10050 Institute of Pharmacology and Toxicology610 Medicine & healthHuman leukocyte antigenBiologyEpitopeCell LineAntigenAntigens NeoplasmImmunology and AllergyCytotoxic T cellHumansAmino Acid SequenceAntigen-presenting cellMelanomaHLA-DRB4Alleles2403 ImmunologyHLA class II–restricted NY-ESO-1 epitopesMembrane ProteinsProteinsT lymphocyteDendritic CellsHLA-DR AntigensVirologyRecombinant ProteinsHistocompatibilityImmunologyCD4+ T cell recognition2723 Immunology and Allergy570 Life sciences; biologyOriginal ArticleHLA-DRB4 Chains
researchProduct

A trifunctional dextran-based nanovaccine targets and activates murine dendritic cells, and induces potent cellular and humoral immune responses in v…

2013

Dendritic cells (DCs) constitute an attractive target for specific delivery of nanovaccines for immunotherapeutic applications. Here we tested nano-sized dextran (DEX) particles to serve as a DC-addressing nanocarrier platform. Non-functionalized DEX particles had no immunomodulatory effect on bone marrow (BM)-derived murine DCs in vitro. However, when adsorbed with ovalbumine (OVA), DEX particles were efficiently engulfed by BM-DCs in a mannose receptor-dependent manner. A DEX-based nanovaccine containing OVA and lipopolysaccharide (LPS) as a DC stimulus induced strong OVA peptide-specific CD4(+) and CD8(+) T cell proliferation both in vitro and upon systemic application in mice, as well a…

CD4-Positive T-LymphocytesLipopolysaccharidesOvalbumin610 Medizinlcsh:MedicineBone Marrow CellsReceptors Cell SurfaceCD8-Positive T-LymphocytesMiceTh2 Cells610 Medical sciencesAnimalsLectins C-Typelcsh:ScienceCell ProliferationImmunity CellularVaccineslcsh:RDextransDendritic CellsImmunity HumoralMannose-Binding LectinsNanoparticleslcsh:QAdsorptionMannose ReceptorResearch ArticlePLoS ONE
researchProduct

Effect of female genital schistosomiasis and anti-schistosomal treatment on monocytes, CD4+ T-cells and CCR5 expression in the female genital tract

2014

Published version of an article from the journal: PLoS One. Also available from the publisher: http://dx.doi.org/10.1371/journal.pone.0098593 BACKGROUND: Schistosoma haematobium is a waterborne parasite that may cause female genital schistosomiasis (FGS), characterized by genital mucosal lesions. There is clinical and epidemiological evidence for a relationship between FGS and HIV. We investigated the impact of FGS on HIV target cell density and expression of the HIV co-receptor CCR5 in blood and cervical cytobrush samples. Furthermore we evaluated the effect of anti-schistosomal treatment on these cell populations. DESIGN: The study followed a case-control design with post treatment follow…

CD4-Positive T-LymphocytesViral DiseasesGynecologic InfectionsVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Tropical medicine: 761Gene Expressionlcsh:MedicineGlobal HealthMonocytesPraziquantelWhite Blood CellsImmunodeficiency VirusesAnimal CellsMedicine and Health SciencesSchistosomiasisPublic and Occupational Healthlcsh:ScienceT CellsCoinfectionObstetrics and GynecologyGenitalia FemaleAIDSInfectious DiseasesPhenotypeMedical MicrobiologyHelminth InfectionsViral PathogensSchistosoma haematobiumFemaleCellular TypesResearch ArticleNeglected Tropical DiseasesAdultAdolescentReceptors CCR5Immune CellsUrologyImmunologySexually Transmitted DiseasesMicrobiologyImmunophenotypingYoung AdultParasitic DiseasesAnimalsHumansMicrobial PathogensBlood CellsGenitourinary Infectionslcsh:RBiology and Life SciencesHIVCell BiologyTropical DiseasesCase-Control StudiesWomen's HealthClinical Immunologylcsh:QGenital Diseases Female
researchProduct

CATs and HATs: the SLC7 family of amino acid transporters

2004

The SLC7 family is divided into two subgroups, the cationic amino acid transporters (the CAT family, SLC7A1-4) and the glycoprotein-associated amino acid transporters (the gpaAT family, SLC7A5-11), also called light chains or catalytic chains of the hetero(di)meric amino acid transporters (HAT). The associated glycoproteins (heavy chains) 4F2hc (CD98) or rBAT (D2, NBAT) form the SLC3 family. Members of the CAT family transport essentially cationic amino acids by facilitated diffusion with differential trans-stimulation by intracellular substrates. In some cells, they may regulate the rate of NO synthesis by controlling the uptake of l-arginine as the substrate for nitric oxide synthase (NOS…

CD98Amino Acid Transport System y+PhysiologyStereochemistryClinical Biochemistry610 Medicine & healthLarge Neutral Amino Acid-Transporter 11308 Clinical BiochemistryImmunoglobulin light chain142-005 142-0052737 Physiology (medical)CationsPhysiology (medical)medicineAnimalsHumansAmino Acidschemistry.chemical_classificationbiologySystem LBiological TransportTransporter1314 Physiologymedicine.diseaseLysinuric protein intoleranceAmino acidchemistryBiochemistryMultigene Familybiology.protein570 Life sciences; biologyCotransporterPfl�gers Archiv European Journal of Physiology
researchProduct

"Table 12" of "Measurement of the inclusive jet cross-section in p anti-p collisions at s**(1/2) =1.96-TeV"

1970

Correction factors for hadronization, underlying event and total non-perturbative effects for the absolute value of the jet rapidity in the range 0.4 to 0.8.

CORRECTIONInclusive20477612047761PBAR P --> JET XHigh Energy Physics::ExperimentAstrophysics::Cosmology and Extragalactic AstrophysicsJet Production
researchProduct

"Table 7" of "Measurement of the inclusive jet cross-section in p anti-p collisions at s**(1/2) =1.96-TeV"

1970

Correction factors for hadronization, underlying event and total non-perturbative effects for the absolute value of the jet rapidity in the range 0.0 to 0.4.

CORRECTIONInclusive20477612047761PBAR P --> JET XHigh Energy Physics::ExperimentAstrophysics::Cosmology and Extragalactic AstrophysicsJet ProductionAstrophysics::Galaxy Astrophysics
researchProduct

"Table 22" of "Measurement of the inclusive jet cross-section in p anti-p collisions at s**(1/2) =1.96-TeV"

1970

Correction factors for hadronization, underlying event and total non-perturbative effects for the absolute value of the jet rapidity in the range 1.2 to 1.6.

CORRECTIONInclusive20477612047761PBAR P --> JET XHigh Energy Physics::ExperimentJet Production
researchProduct